BioSpace News Archive

Spero Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation for oral SPR720 for the treatment of nontuberculous mycobacterial infection..

RenovaCare, Inc. today announced new corporate headquarters in Roseland, New Jersey and laboratory facilities in Berlin, Germany to advance the development of its patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues.

Amir Jafri, CEO of Immunicom, Inc., a medical technology company that has been awarded FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating stage IV metastatic cancer, was one of five exclusively invited guest panelists at Congressman Dan Crenshaw’s second annual Healthcare Innovation Summit held at Rice University.

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that it has received a Research and Development (R&D) Tax Incentive cash rebate of $850,000 from the Australian Tax Office.

Carestream Health earned the highest position in TractManager’s MD Buyline User Satisfaction Ratings across three categories—portables, X-ray detectors and room-based digital radiography systems—during 2019 survey periods.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has completed a scan of selected RCKMC’s cannabis strains.

INmune Bio, Inc. today reported its financial results for the fourth quarter and full year ended December 31, 2019 and is providing a business update.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights on March 23, 2020.

Company doubles its customer portfolio and increases oncology prior authorization platform usage to 5 million health plan members

The Exclusive Research Report on “Acral Lentiginous Melanoma Drugs Market with Industry-Primary Research, Secondary Research, Product Research, Revenue, Emerging Trends and Top Growing Companies 2020-2029”.